GSK and Genmab Announce Topline Results from a Pivotal Head to Head Study of Ofatumumab in Combination With Chemotherapy vs Rituximab in Combination with Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma LONDON and COPENHAGEN, Denmark, May 19, 2014 -- GlaxoSmithKline plc UK:GSK +0.03% and Genmab A/S announced ... (more)
http://ift.tt/SeqJt3
http://ift.tt/SeqJt3
No comments:
Post a Comment